Introduction {#Sec1}
============

In chronic obstructive pulmonary disease (COPD), real-world adherence to maintenance therapy can be as low as 20%.^[@CR1]^ In contrast, trials report adherence rates of over 80% in most participants.^[@CR2]^ Previous studies showed that patients with high adherence have significantly better clinical and economic outcomes.^[@CR3]^ Consequently, interventions focusing on adherence enhancement have shown to be effective and cost-effective.^[@CR4],[@CR5]^ Yet, in these studies, only average adherence was assessed and no distinction was made between the different aspects of non-adherence. Optimal implementation of inhaled therapy involves both regular use as well as good inhaler technique.^[@CR6]^ In our previous work, we identified four distinct clusters of inhaler adherence that were associated with differential clinical outcomes.^[@CR7]^ Economic evaluations of adherence-enhancing interventions in each of those clusters have not been performed, but could help prioritizing specific target populations for tailored interventions. The aim of this follow-up study is to estimate the potential cost-effectiveness of reaching optimal adherence in each suboptimal adherence cluster.

Results {#Sec2}
=======

The study's baseline population characteristics (*n* = 226) have been described elsewhere.^[@CR1],[@CR7]^ In short, cluster 1 had the lowest mortality during follow-up. Cluster 2 had the highest rate of antibiotic and/or oral steroids community prescriptions. The highest overall healthcare use was attributable to patients from cluster 3. Cluster 4 had the highest mortality (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Proportional contribution of each adherence cluster to all-cause clinical outcomes over the 12-month follow-up period (adjusted for the number of participants per cluster). Reported differences are the absolute differences in the proportion of events attributable to cluster 3 vs. cluster 1 for emergency department and hospital admission and cluster 4 vs. cluster 1 for death. \^ denotes *p* = 0.05, \**p* \< 0.05

Cost-effectiveness {#Sec3}
------------------

Cost-effectiveness analysis results are shown in Table [1](#Tab1){ref-type="table"}. Adherence-enhancing interventions seem generally cost-effective, given all ICERs are below the Irish cost-effectiveness threshold of €45,000/QALY.^[@CR8]^ In other words, this means that all adherence-enhancing interventions would cost less than €45,000 to gain one life-year in perfect health. For each cluster, the theoretical intervention would result in additional life years and QALYs gained. Notably, for cluster 3, an intervention would be cost-saving (i.e., less costs and more QALYs).Table 1Cost-effectiveness of enhancing adherence based on a 5-year time horizonClusterTotal costsIntervention costs^a^Medication costsHealthcare costsLife yearsQALYs*Cluster 2: Regular use, frequent technique errors*Intervention€11,386€184€2901€83003.753.00Cluster 2€10,150€0€2723€74283.522.81Difference€1235€184€179€8720.230.19ICER€6520/QALY gained*Cluster 3: Irregular use, good technique*Intervention€11,812€184€2936€86923.803.03Cluster 3€12,657€0€2395€10,2623.402.70Difference−€845€184€541−€15700.390.33ICERCost-saving (i.e., less costs, more QALYs)*Cluster 4: Irregular use, frequent technique errors*Intervention€13,075€184€3000€98913.883.10Cluster 4€10,180€0€1918€82612.982.36Difference€2896€184€1082€16300.900.74ICER€3935/QALY gained*ICER* incremental cost-effectiveness ratio, *QALY* quality-adjusted life year^a^Note that the mean per-patient intervention costs are slightly lower given some patients die within the first year and so do not cost the full €200

Discussion {#Sec4}
==========

We performed exploratory cost-effectiveness modeling to assess the potential economic benefits of improved adherence in three clusters of patients with suboptimal adherence. In all clusters, interventions seem cost-effective. Moreover, in patients with irregular use but good inhaler technique, a possible cost-saving of €845/annum/person could be yielded despite the higher cost of medication arising from better adherence.

Remote monitoring of adherence on a longitudinal basis provides an accurate evaluation of regularity of use as well as inhaler technique. The use of a technology, such as the one described in this report, identified four patterns of adherence and may give guidance as to how we might approach this challenge in a personalized manner. Hence, in the future, by providing personalized interventions to the highest risk groups we may both improve adherence and have a positive impact on both clinical and economic outcomes in those most in need, such as those in cluster 3. The need for personalized adherence-enhancing interventions has recently been highlighted.^[@CR9]^ They could include education and training on inhaler technique for those with frequent technique errors, patient reminders for those with irregular use due to forgetfulness, and shared decision-making and motivational interviewing for those with irregular use due to a conscious, intentional decision.^[@CR9]^

This study is a first attempt to estimate the cost-effectiveness of interventions in different adherence clusters, but was limited by the use of post hoc and short-term effectiveness data for the different clusters. Regarding generalizability, absolute costs may differ per country or setting, but we expect relative cluster results to be comparable. Our exploratory cost-effectiveness model estimates should be confirmed when long-term clinical intervention trial data become available, including extensive sensitivity and scenario analyses as well as analyses in a non-admitted primary care COPD population.

Conclusion {#Sec5}
==========

Personalized adherence interventions targeting patient-specific regularity of inhaler use and inhaler technique could result in clinical and economic benefits for COPD patients.

Methods {#Sec6}
=======

Study design {#Sec7}
------------

This was an exploratory cost-effectiveness analysis. Ethical approval for the clinical study was obtained from the Beaumont Hospital Ethics Committee.

Patient population {#Sec8}
------------------

Patient selection and data collection has been described previously.^[@CR1]^ Briefly, hospitalized patients with COPD, prescribed salmeterol/fluticasone propionate (Seretide®, GlaxoSmithKline, Ireland), were included and written informed consent was obtained from all participants.

Inhaler adherence {#Sec9}
-----------------

Adherence was assessed using the INCA^TM^ device that can track both timing and quality of inhaler use.^[@CR1]^ The INCA acoustic recordings allowed for identification of the following four adherence clusters:^[@CR7]^ (1) regular use/good technique, (2) regular use/frequent technique errors, (3) irregular use/good technique, and (4) irregular use/frequent technique errors. Cluster-specific healthcare utilization and mortality was studied previously^[@CR7]^ and is summarized in Fig. [1](#Fig1){ref-type="fig"}.

Cost-effectiveness analysis {#Sec10}
---------------------------

The cost-effectiveness of enhanced adherence, i.e., the theoretical shift of patients from poor adherence (i.e., cluster 2, 3, or 4) to good adherence (i.e., cluster 1), was estimated. Therefore, a previously developed, described, and validated health-economic model^[@CR5]^ was used and populated with Irish and INCA-specific cost (for medication, intervention, and healthcare utilization) and effect (mortality and exacerbations) data (Appendix [1](#MOESM1){ref-type="media"}). The model has received a high-quality score in the latest COPD model review,^[@CR10]^ and estimates the incremental cost-effectiveness ratio (ICER) in terms of costs (2013, €) per quality-adjusted life-year (QALY) gained from the Irish healthcare payer's perspective assuming fixed per-patient intervention costs of €200 (authors' estimation). Three ICERs were calculated using cluster 1 as intervention and clusters 2, 3, and 4, respectively, as usual care scenarios. In line with recommendations,^[@CR11]^ a policy-relevant time horizon of 5 years was used, taking into account a 5% discount rate for both costs and effects as per Irish Health Information and Quality Authority guidelines ([www.hiqa.ie](http://www.hiqa.ie)).

Data availability statement {#Sec11}
---------------------------

Detailed data and characteristics of the study population are available in ref. ^[@CR1]^ and other data that support the findings of this study are available from the corresponding author on reasonable request.
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Appendix 1: Input parameters for cost-effectiveness model
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